Teos announced in May it was winding down operations, following disappointing Phase II study results for its anti-TIGIT antibody.

The FDA had made the request Friday, which Sarepta initially rebuffed, following the death of a third patient treated with one of the firm's gene therapies.

Researchers explored changes in survival outcomes and financial strain for NSCLC patients during a time when new targeted therapies were hitting the market.

The study will compare neladalkib to Genentech's ALK inhibitor Alecensa in patients who've had no prior systemic treatment.

The FDA requested Sarepta voluntarily stop distributing Elevidys after the death of a third patient who received one of the firm's gene therapies.

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

For $1.8 million upfront and additional contingent and milestone payments, I-Mab gains full rights to givastomig's parental antibody.

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

The firm will combine every 15 shares into one share in order to comply with Nasdaq's minimum bid price requirement.